Drugdocs | Ajovy

An independent source of information on U.S. brand name drugs for health professionals

An independent source of information on U.S. brand name drugs for health professionals

Ajovy

Chemical Name	fremanezumab-vfrm
Dosage Form	Injection (subcutaneously; 225 mg)
Drug Class	Monoclonal antibodies
System	Nervous
Company	Teva Pharmaceuticals USA, Inc.
Approval Year	2018

Indication

To prevent migraines in adults.

Last updated on 11/9/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document Title	Year	Source
Ajovy (Fremanezumab-vfrm) Prescribing Information	2018	Teva Pharmaceuticals USA, North Wales, PA

Document Title	Year	Source
Fremanezumab for preventing migraine.	2020	NICE

Document Title	Year	Source
Safety and efficacy of fremanezumab for the prevention of migraine: A meta-analysis from randomized controlled trials.	2020	Frontiers in Neurology
Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine - an updated systematic review and meta-analysis.	2020	BMC Neurology
CGRP, a target for preventive therapy in migraine and cluster headache: Systematic review of clinical data.	2019	Cephalalgia

Document Title	Year	Source
European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention.	2019	The Journal of Headache and Pain